Study (author/year) | Sample size (I/C) | Average courses (\( \overline{\mathrm{X}} \)[SD]) | Interventions | Course of treatment | Used instruments in the study | ||
---|---|---|---|---|---|---|---|
T | C | T | C | ||||
Pi 2006 [13] | 21/22 | 1.30 [2.03] y | TG + Mizolastine | Mizolastine | ≤12 w | LFS, SSRI, ADE | |
Zhang 2007 [14] | 86/82 | 0.85 y | TwHF + Levocetirizine | Levocetirizine | 4 w | LFS, SSRI, ADE | |
Bao 2008 [15] | 87/80 | 1.60 y | GTT + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE | |
Xu2009 [16] | 54/54 | 1.08 y | 1.17 y | TG + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE, RER |
Wei 2010 [17] | 90/90 | 6.25 y | 6.20 y | GTT + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE, DLQI |
Zhong 2011 [18] | 40/38 | 16.75 y | 16.25 y | THH + Cetirizine Hydrochloride | Placebo + Cetirizine Hydrochloride | 4 w | LFS, TER, ADE |
Liu 2011 [19] | 98/90 | 16.20 [0.96] y | GTT + Levocetirizine Hydrochloride | Levocetirizine Hydrochloride | 4 w | LFS, SSRI, ADE | |
Qian 2011 [9] | 180/180 | 6.72 [3.47] y | 6.51 [3.76] y | TG + Loratadine; TG + Mizolastine; TG + Cetirizine | Loratadine; Mizolastine; Cetirizine | 4 w | LFS, UAS,S SRI, ADE, DLQI, RER |
Yu 2011 [20] | 48/47 | 1.7 y | THH + Terfenadine | Terfenadine | 4 w | SA, ADE | |
Lu 2012 [21] | 40/40 | 3.20 [1.60] y | 3.20 [1.20] y | TG + Fexofenadine hydrochloride | Fexofenadine hydrochloride | 4 w | LFS, SSRI, ADE |
Zhou 2012 [22] | 60/60 | 3.97 [2.97] y | 3.45 [2.72] y | THH + Mizolastine + Ketotifena | Mizolastine + Ketotifena | 8 w | UAS, SSRI, ADE |
Fan 2013 [23] | 43/41 | 2.70 y | 2.77 y | GTT + Ebastine | Ebastine | 4 w | LFS, SSRI |
Liu 2013 [24] | 89/90 | ≥0.13 y | TG + Cetirizine Hydrochloride | Cetirizine Hydrochloride | 4 w | LFS, VAS, SSRI, ADE, RER | |
Zheng 2013 [25] | 37/37 | ≥0.13 y | GTT + Desloratadine | Desloratadine | 4 w | LFS ,SSRI, ADE,DLQI, RER | |
Chen 2014 [26] | 45/46 | 3.70 [1.30] y | 3.90 [1.10] y | GTT + Fexofenadine | Fexofenadine | 4 w | UAS, VAS, LFS, ADE |
Wang 2014 [27] | 32/32 | ≥0.13 y | GTT + Desloratadine | Desloratadine | 4 w | SA, ADE | |
Zhou 2014 [28] | 60/60 | ≥0.13 y | GTT + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE, RER | |
Li 2016 [29] | 36/34 | ≥0.13 y | TG + Ebastine | Ebastine | 4 w | SA, ADE | |
Liu 2016 [30] | 60/60 | 0.53 [0.27] y | 0.58 [0.33] y | GTT + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE, DLQI |
Chen 2017 [31] | 45/45 | 0.56 [0.32] y | 0.53 [0.27] y | GTT + Desloratadine | Desloratadine | 4 w | SA, ADE |
Tao 2017 [32] | 48/49 | 2.46 [0.52] y | 2.53 [0.63] y | GTT + Desloratadine | Desloratadine | 4 w | LFS, SSRI, ADE, DLQI, RER |